An innovation in sterilization.

Increasing the safety of human allograft bone grafts is of significant importance and of great benefit to patients. Often, the decision to use an autograft rather than an allograft tissue is based on the perceived risk of viral or bacterial transmission.

Until now, very limited technologies have been capable of substantially reducing all types of pathogens in biological products, while maintaining the integrity of the underlying bio active properties in the product. Various current sterilization and cleansing methods exist but can destroy limited or specific types of pathogens (such as bacteria or lipid enveloped viruses).

UltraGraft™ Patient Benefits: Safety and High Performance

T106 Terminal Sterilization System™ was developed to address both of these issues when it comes to allograft tissue. Through our proprietary cold chemical sterilization process performed in our certified Cleanrooms we were able to:

  • Achieve tissue sterilization to SAL=-6 (true sterility) after packaging
  • Preserve the tissue collagen and biomechanical structure to increase performance of the graft

UltraGraft™ Non-Irradiated & Sterile Key Benefits

  • Sterile implant offering 100% confidence
  • Greater bio compatibility offering greater osteoinductivity (ability to induce new bone growth in patients) and osteoconductivity (provide new bone growth a scaffolding to grow into)
  • Greater structural integrity providing stronger more resilient implants
  • Validated sterilization method using the overkill method, the most stringent of validation methods

Validated testing

Testing proves T106 Terminal Sterilization System™ substantially inactivates these types of known pathogens, including Clostridium sporogenes a more common and resistant pathogen than C. sordellii, in allograft tissue products.